Kinarus Therapeutics Holding AG
KNRS | SW
Overview
Corporate Details
- ISIN(s):
- CH1330780979
- LEI:
- 506700VDL70GGMHR5758
- Country:
- Switzerland
- Address:
- Hochbergerstrasse 60C, 4057 Basel
- Website:
- https://www.curatis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Formerly Kinarus Therapeutics Holding AG, the company was renamed Curatis Holding AG in April 2024 following a business combination with Curatis AG. The new entity is a specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. The company operates two business segments: a distribution arm that licenses and promotes over 40 third-party orphan and specialty medicines in Switzerland with plans for European expansion, and a development arm focused on a pipeline of novel drugs. Its development strategy prioritizes compounds with existing safety data to lower risk and accelerate commercialization, with programs targeting pediatric brain edema, severe migraine, medication overuse headache, and rare inflammatory and fibrotic diseases.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Kinarus Therapeutics Holding AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-05 07:00 |
Regulatory News Service
Curatis expands distribution business with Phoenix Labs with up to CHF 5m addit…
|
English | 6.3 KB | |
| 2025-09-05 02:00 |
Regulatory News Service
Curatis expands distribution business with Phoenix Labs with up to CHF 5m addit…
|
English | 7.8 KB | |
| 2025-07-31 06:00 |
Legal Proceedings Report
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
|
English | 8.0 KB | |
| 2025-07-31 02:00 |
Legal Proceedings Report
FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
|
English | 9.7 KB | |
| 2025-05-25 11:31 |
Post-Annual General Meeting Information
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 7.1 KB | |
| 2025-05-24 02:00 |
Post-Annual General Meeting Information
Annual General Meeting of Curatis Holding AG approved all proposals of the Boar…
|
English | 8.8 KB | |
| 2025-05-23 07:00 |
Regulatory News Service
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 13.1 KB | |
| 2025-05-23 02:00 |
Regulatory News Service
Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opport…
|
English | 15.4 KB | |
| 2025-05-23 00:00 |
Investor Presentation
Investor Presentation
|
English | 958.3 KB | |
| 2025-05-02 00:00 |
Registration Form
Articles of Incorporation
|
German | 2.0 MB | |
| 2025-03-27 07:00 |
Earnings Release
Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patient…
|
German | 20.6 KB | |
| 2025-03-27 01:00 |
Earnings Release
Curatis: Umsatzwachstum von 30% im Vertrieb - dazu deutliche Ausweitung Patient…
|
German | 23.8 KB | |
| 2025-03-27 00:00 |
Investor Presentation
Investor Presentation
|
English | 1.1 MB | |
| 2025-03-27 00:00 |
Annual Report
Annual Report 2024
|
English | 1.4 MB | |
| 2025-03-12 07:00 |
Board/Management Information
Curatis Announces Formation of Distinguished Advisory Board
|
English | 10.3 KB |
Automate Your Workflow. Get a real-time feed of all Kinarus Therapeutics Holding AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kinarus Therapeutics Holding AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-04-25 | N/A | Non-Executive member | Buy | None | 1.11 CHF |
| 2023-10-31 | N/A | Executive member | Sell | None | 4,248.75 CHF |
| 2023-09-07 | N/A | Executive member | Sell | None | 11,713.02 CHF |
| 2023-06-23 | N/A | Executive member | Sell | None | 45,028.85 CHF |
| 2023-06-13 | N/A | Executive member | Sell | None | 38,761.94 CHF |
| 2023-06-05 | N/A | Executive member | Sell | None | 1,417,143.65 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 7,441,035.53 CHF |
| 2022-06-02 | N/A | Non-Executive member | Buy | None | 2,483,942.78 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 922,192.69 CHF |
| 2022-06-02 | N/A | Executive member | Buy | None | 399,716.30 CHF |
